![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RELB |
Gene summary for RELB |
![]() |
Gene information | Species | Human | Gene symbol | RELB | Gene ID | 5971 |
Gene name | RELB proto-oncogene, NF-kB subunit | |
Gene Alias | I-REL | |
Cytomap | 19q13.32 | |
Gene Type | protein-coding | GO ID | GO:0001773 | UniProtAcc | Q01201 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5971 | RELB | LZE4T | Human | Esophagus | ESCC | 4.57e-07 | 2.16e-01 | 0.0811 |
5971 | RELB | LZE8T | Human | Esophagus | ESCC | 4.57e-02 | 4.96e-02 | 0.067 |
5971 | RELB | LZE20T | Human | Esophagus | ESCC | 1.34e-09 | 2.39e-01 | 0.0662 |
5971 | RELB | LZE22T | Human | Esophagus | ESCC | 5.88e-09 | 8.46e-01 | 0.068 |
5971 | RELB | LZE24T | Human | Esophagus | ESCC | 9.79e-22 | 7.05e-01 | 0.0596 |
5971 | RELB | LZE21T | Human | Esophagus | ESCC | 3.25e-06 | 3.86e-01 | 0.0655 |
5971 | RELB | P1T-E | Human | Esophagus | ESCC | 1.73e-23 | 1.25e+00 | 0.0875 |
5971 | RELB | P2T-E | Human | Esophagus | ESCC | 6.11e-76 | 1.58e+00 | 0.1177 |
5971 | RELB | P4T-E | Human | Esophagus | ESCC | 3.83e-60 | 1.30e+00 | 0.1323 |
5971 | RELB | P5T-E | Human | Esophagus | ESCC | 2.84e-53 | 1.20e+00 | 0.1327 |
5971 | RELB | P8T-E | Human | Esophagus | ESCC | 2.49e-48 | 1.43e+00 | 0.0889 |
5971 | RELB | P9T-E | Human | Esophagus | ESCC | 3.52e-19 | 5.29e-01 | 0.1131 |
5971 | RELB | P10T-E | Human | Esophagus | ESCC | 7.04e-31 | 1.02e+00 | 0.116 |
5971 | RELB | P11T-E | Human | Esophagus | ESCC | 1.11e-26 | 9.17e-01 | 0.1426 |
5971 | RELB | P12T-E | Human | Esophagus | ESCC | 7.02e-20 | 5.69e-01 | 0.1122 |
5971 | RELB | P15T-E | Human | Esophagus | ESCC | 6.66e-28 | 7.43e-01 | 0.1149 |
5971 | RELB | P16T-E | Human | Esophagus | ESCC | 3.67e-39 | 8.24e-01 | 0.1153 |
5971 | RELB | P17T-E | Human | Esophagus | ESCC | 5.36e-18 | 7.61e-01 | 0.1278 |
5971 | RELB | P19T-E | Human | Esophagus | ESCC | 6.90e-15 | 1.01e+00 | 0.1662 |
5971 | RELB | P20T-E | Human | Esophagus | ESCC | 2.68e-32 | 9.20e-01 | 0.1124 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0062197111 | Esophagus | ESCC | cellular response to chemical stress | 234/8552 | 337/18723 | 5.37e-19 | 5.97e-17 | 234 |
GO:000724919 | Esophagus | ESCC | I-kappaB kinase/NF-kappaB signaling | 183/8552 | 281/18723 | 3.02e-11 | 1.01e-09 | 183 |
GO:007121419 | Esophagus | ESCC | cellular response to abiotic stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
GO:010400419 | Esophagus | ESCC | cellular response to environmental stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
GO:0030099111 | Esophagus | ESCC | myeloid cell differentiation | 232/8552 | 381/18723 | 1.22e-09 | 2.90e-08 | 232 |
GO:000257317 | Esophagus | ESCC | myeloid leukocyte differentiation | 128/8552 | 208/18723 | 2.75e-06 | 3.15e-05 | 128 |
GO:003292215 | Esophagus | ESCC | circadian regulation of gene expression | 48/8552 | 68/18723 | 2.76e-05 | 2.30e-04 | 48 |
GO:00069707 | Esophagus | ESCC | response to osmotic stress | 57/8552 | 84/18723 | 3.26e-05 | 2.70e-04 | 57 |
GO:00326084 | Esophagus | ESCC | interferon-beta production | 40/8552 | 56/18723 | 8.36e-05 | 6.08e-04 | 40 |
GO:00326484 | Esophagus | ESCC | regulation of interferon-beta production | 40/8552 | 56/18723 | 8.36e-05 | 6.08e-04 | 40 |
GO:00714707 | Esophagus | ESCC | cellular response to osmotic stress | 31/8552 | 41/18723 | 9.32e-05 | 6.68e-04 | 31 |
GO:001988225 | Esophagus | ESCC | antigen processing and presentation | 67/8552 | 106/18723 | 2.03e-04 | 1.28e-03 | 67 |
GO:003247912 | Esophagus | ESCC | regulation of type I interferon production | 61/8552 | 95/18723 | 2.05e-04 | 1.29e-03 | 61 |
GO:003260612 | Esophagus | ESCC | type I interferon production | 61/8552 | 95/18723 | 2.05e-04 | 1.29e-03 | 61 |
GO:004851118 | Esophagus | ESCC | rhythmic process | 164/8552 | 298/18723 | 6.80e-04 | 3.57e-03 | 164 |
GO:000762319 | Esophagus | ESCC | circadian rhythm | 119/8552 | 210/18723 | 8.47e-04 | 4.36e-03 | 119 |
GO:004211018 | Esophagus | ESCC | T cell activation | 256/8552 | 487/18723 | 1.18e-03 | 5.87e-03 | 256 |
GO:19031317 | Esophagus | ESCC | mononuclear cell differentiation | 226/8552 | 426/18723 | 1.20e-03 | 5.88e-03 | 226 |
GO:00380615 | Esophagus | ESCC | NIK/NF-kappaB signaling | 81/8552 | 143/18723 | 5.33e-03 | 2.00e-02 | 81 |
GO:00302176 | Esophagus | ESCC | T cell differentiation | 137/8552 | 257/18723 | 8.09e-03 | 2.87e-02 | 137 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa046259 | Esophagus | ESCC | C-type lectin receptor signaling pathway | 73/4205 | 104/8465 | 1.57e-05 | 7.98e-05 | 4.09e-05 | 73 |
hsa040645 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
hsa05166310 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa0516937 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa0462513 | Esophagus | ESCC | C-type lectin receptor signaling pathway | 73/4205 | 104/8465 | 1.57e-05 | 7.98e-05 | 4.09e-05 | 73 |
hsa0406412 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
hsa0516614 | Liver | Cirrhotic | Human T-cell leukemia virus 1 infection | 87/2530 | 222/8465 | 1.69e-03 | 8.01e-03 | 4.94e-03 | 87 |
hsa0516914 | Liver | Cirrhotic | Epstein-Barr virus infection | 80/2530 | 202/8465 | 1.80e-03 | 8.33e-03 | 5.13e-03 | 80 |
hsa0516615 | Liver | Cirrhotic | Human T-cell leukemia virus 1 infection | 87/2530 | 222/8465 | 1.69e-03 | 8.01e-03 | 4.94e-03 | 87 |
hsa0516915 | Liver | Cirrhotic | Epstein-Barr virus infection | 80/2530 | 202/8465 | 1.80e-03 | 8.33e-03 | 5.13e-03 | 80 |
hsa0516921 | Liver | HCC | Epstein-Barr virus infection | 128/4020 | 202/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 128 |
hsa0516622 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
hsa0516931 | Liver | HCC | Epstein-Barr virus infection | 128/4020 | 202/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 128 |
hsa0516632 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
hsa0516616 | Lung | IAC | Human T-cell leukemia virus 1 infection | 49/1053 | 222/8465 | 3.44e-05 | 6.38e-04 | 4.24e-04 | 49 |
hsa040108 | Lung | IAC | MAPK signaling pathway | 62/1053 | 302/8465 | 3.54e-05 | 6.38e-04 | 4.24e-04 | 62 |
hsa04625 | Lung | IAC | C-type lectin receptor signaling pathway | 26/1053 | 104/8465 | 3.15e-04 | 3.11e-03 | 2.06e-03 | 26 |
hsa0516916 | Lung | IAC | Epstein-Barr virus infection | 40/1053 | 202/8465 | 1.72e-03 | 9.66e-03 | 6.41e-03 | 40 |
Page: 1 2 3 4 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RELB | SNV | Missense_Mutation | novel | c.1395N>A | p.Asp465Glu | p.D465E | Q01201 | protein_coding | deleterious(0.01) | benign(0.092) | TCGA-CR-7370-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RELB | SNV | Missense_Mutation | rs754531882 | c.1237C>T | p.Arg413Trp | p.R413W | Q01201 | protein_coding | deleterious(0) | possibly_damaging(0.856) | TCGA-CV-A6K1-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
RELB | SNV | Missense_Mutation | novel | c.443N>T | p.Ser148Leu | p.S148L | Q01201 | protein_coding | deleterious(0.01) | possibly_damaging(0.891) | TCGA-IQ-A61I-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
RELB | SNV | Missense_Mutation | novel | c.241C>T | p.Arg81Cys | p.R81C | Q01201 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
RELB | SNV | Missense_Mutation | novel | c.590N>A | p.Ser197Asn | p.S197N | Q01201 | protein_coding | tolerated(0.23) | possibly_damaging(0.602) | TCGA-B7-A5TI-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | eloxatin | CR |
RELB | SNV | Missense_Mutation | rs770578374 | c.1687N>T | p.Arg563Cys | p.R563C | Q01201 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.892) | TCGA-BR-4370-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RELB | SNV | Missense_Mutation | c.1406N>A | p.Gly469Asp | p.G469D | Q01201 | protein_coding | tolerated(0.07) | benign(0.133) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RELB | SNV | Missense_Mutation | c.418N>C | p.Phe140Leu | p.F140L | Q01201 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BR-8372-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | etoposide | CR | |
RELB | SNV | Missense_Mutation | c.1535N>G | p.Ala512Gly | p.A512G | Q01201 | protein_coding | deleterious_low_confidence(0) | benign(0.014) | TCGA-CD-8529-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | epirubicin | CR | |
RELB | SNV | Missense_Mutation | rs61735620 | c.1690N>A | p.Glu564Lys | p.E564K | Q01201 | protein_coding | deleterious_low_confidence(0) | benign(0.046) | TCGA-F1-A448-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |